Evidence map›Paper›PMID 40677917›Full record

ArticleFrontiers in cell and developmental biology2025

Temporal dynamics of gene and protein signatures following volumetric muscle loss.

Ishita Jain, Beu P Oropeza, Caroline Hu, Gladys Chiang, Sree Aravindan, Renato Reyes, Daniel Yuhang Li, Paul Cheng, Ngan F Huang

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ishita Jain *Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.
Beu P Oropeza *Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.
Caroline HuCenter for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, United States.
Gladys ChiangCenter for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, United States.
Sree AravindanCenter for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, United States.
Renato ReyesCenter for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, United States.
Daniel Yuhang LiDivision of Cardiovascular Medicine, Stanford University, Stanford, CA, United States.
Paul ChengDivision of Cardiovascular Medicine, Stanford University, Stanford, CA, United States.
Ngan F HuangDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, United States.

Funding

Development of a Bioengineered Therapeutic Device for the Prevention of LymphedemaR01CA285372 · NCI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Ngan F. Huang, Michael Vitoldovich Paukshto · 2024 to 2026
$1.6M
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery DiseaseK08HL153798 · NHLBI · STANFORD UNIVERSITY · PI CHENG, PAUL PO SHENG · 2020 to 2024
$933k
Biomaterials for delivery and maintenance of tip endothelial cellsR21HL172096 · NHLBI · UNIVERSITY OF CALIFORNIA, MERCED · PI HUANG, NGAN F., MCCLOSKEY, KARA E · 2024 to 2025
$643k
Enhance Cell Therapies for Peripheral Arterial Disease Using Human-Compatible Protease-Based ControlsR21HL177570 · NHLBI · STANFORD UNIVERSITY · PI GAO, XIAOJING J, HUANG, NGAN F. · 2025 to 2025
$410k
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery DiseaseR41HL170875 · NHLBI · SERINA THERAPEUTICS, INC. · PI HUANG, NGAN F., LEE, JI EUN · 2023 to 2023
$341k
TCF21 is a causal coronary artery disease gene that modulates coronary smooth muscle phenotypic transition via epigenetic mechanismsF32HL165819 · NHLBI · STANFORD UNIVERSITY · PI LI, DANIEL YUHANG · 2022 to 2023
$126k
BLRD VA I01 BX004259BLRD VA I01 BX006882BLRD VA IK6 BX006309NCI NIH HHS R01 CA285372NHLBI NIH HHS F32 HL165819NHLBI NIH HHS K08 HL153798NHLBI NIH HHS R21 HL172096NHLBI NIH HHS R21 HL177570NHLBI NIH HHS R41 HL170875RRD VA I21 RX004898
6 · The paper itself

Abstract

Introduction: Volumetric muscle loss (VML) is characterized by permanent tissue impairment resulting from critically-sized muscle loss. We performed time-series transcriptomic and proteomic analyses to reveal key mediators of irreversible pathological remodeling after induction of VML in mice. Methods: The dynamics of gene and protein expression patterns were analyzed for up to 3 weeks after muscle injury. Results: RNA Sequencing revealed transcriptional patterns that show rapid upregulation or downregulation shortly after injury, among which a subset of genes failed to return to pre-injury levels within 3 weeks after VML. Time-series analysis revealed gene clusters with sustained upregulation after 3 weeks, including those associated with extracellular matrix remodeling and inflammation, whereas the gene clusters having sustained downregulation were associated with mitochondrial function and metabolism. We further identified Discussion: This work demonstrates the utility of time-series analysis to reveal dysregulated pathways in the setting of VML.

Indexed as

gene signaturemuscle regenerationproteomicsRNA sequencingvolumetric muscle loss (VML)

Identifiers

PMID40677917
PMCPMC12268354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.